Microsaic Systems plc Microsaic Enhances Bioprocessing Capabilities
11 May 2017 - 4:01PM
RNS Non-Regulatory
TIDMMSYS
Microsaic Systems plc
11 May 2017
11 May 2017
Microsaic Systems plc
("Microsaic", "Microsaic Systems" or the "Company")
Microsaic enhances capabilities of its 4000 MiD(R) miniaturised
mass spectrometer for bioprocessing applications
Microsaic Systems plc (AIM: MSYS), the developer of chip-based
mass spectrometry (MS) instruments, has developed a novel
technology to enable real-time analysis of proteins in
bioprocessing applications, such as in the manufacture of biologic
molecules (proteins, antibodies and peptides) for therapeutic and
diagnostic uses. The new technology is a tool for rapidly desalting
and purifying protein samples prior to their analysis using
Microsaic's 4000 MiD(R) MS instrument. This new technology has the
potential to significantly accelerate the industrial purification
of biologics.
Glenn Tracey, Microsaic's Chief Operating Officer,
commented:
"The benefits of Microsaic's point of use MS technology, in
combination with its patented innovation for on-line desalting,
allows for the purification of the desired biomolecules in real
time. In doing so, analysis times can be reduced from days or even
weeks to minutes while offering the potential for significant
savings on operational costs. Eight of the top ten selling drugs in
2016 were biologics and the trend for targeted biologic
therapeutics is set to continue. Technologies that can accelerate
and enhance their production therefore present an opportunity for
Microsaic."
Mass spectrometry is a powerful technique which allows the
effective implementation of "QbD" (Quality by Design), a key
industry and regulatory driver for current and future production of
biologics.
Enquiries:
Microsaic Systems plc
Jim Ramage, CEO
Bevan Metcalf, FD +44 (0) 1483 751577
N+1 Singer (Nominated Adviser &
Broker)
Shaun Dobson
Liz Yong +44 (0)20 7496 3000
Citigate Dewe Rogerson (Financial
PR)
Mark Swallow
Marine Perrier +44 (0)20 7638 9571
About Microsaic Systems
Microsaic Systems plc is a high technology company developing
chip-based, bench-top mass spectrometry ("MS") instruments that are
designed to improve the efficiency of Pharma R&D. MS is an
analytical technique of choice for biochemists across many industry
sectors.
Microsaic aims to bring routine MS analysis to the
pharmaceutical scientist, providing powerful methods of analysis to
enable earlier decision making relating to product identification,
purity and bioactivity.
The Company is working with established global companies in
preparative and purification science with expertise in Pharma and
life sciences to co-develop new, integrated and optimised,
application-specific, solutions to improve productivity in the
development of small molecule and novel biologic (peptides,
antibodies) medicines.
The Microsaic 4000 MiD(R), single quadrupole, is the world's
smallest MS system, retaining the functionality of larger
conventional MS systems, is easier to use by non-specialists,
consumes less energy and has lower running costs. The Company is
also developing new MS systems, based on its patented chip
technologies, to address further areas of emerging need in Pharma
R&D.
Microsaic Systems was established in 2001 by a team including
founders from Imperial College London, and was admitted to AIM in
2011 (ticker: MSYS).
www.microsaic.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKKDPNBKDOPD
(END) Dow Jones Newswires
May 11, 2017 02:01 ET (06:01 GMT)
Microsaic Systems (LSE:MSYS)
Historical Stock Chart
From Apr 2024 to May 2024
Microsaic Systems (LSE:MSYS)
Historical Stock Chart
From May 2023 to May 2024